Figure 8
MiR-130b mimic decreases the expression of EMT markers and inhibits renal tubulointerstitial fibrosis in vivo.
(a) Decreased miR-130b in plasma and (b) kidney samples of diabetic rats and miR-130b mimic upregulated its expression. (c) MiR-130b mimic decreased Snail, Vimentin, Collagen IV and α-SMA, but increased E-cadherin by qRT-PCR and (d) Western blot analysis. (e) MiR-130b mimic downregulated the level of SNAIL, VIMENTIN, COLLAGEN IV and α-SMA, but increased E-CADHERIN by immunohistochemistry. (f) Improved renal tubulointerstitial fibrosis in diabetic rats treated with miR-130b mimic by MTS. (g) Quantification of the staining intensity for immunohistochemistry (left panel) and interstitial injury score (right panel). (h) A hypothetical model illustrated that miR-130b regulates renal tubulointerstitial fibrosis through Snail/Ecadherin-mediated EMT process in diabetic nephropathy. Results are presented as mean ± SD of three independent experiments. *P < 0.05; #P < 0.0001. NC, normal control; DM, diabete mellitus; DM_miR-NC, diabetic rats treated with miRNA mimic negative control; DM_miR-130bm, diabetic rats treated with miR-130b mimic; MTS, Masson’ s trichrome stain.
